COMPANY PROFILE

Altesa BioSciences

Altesa Biosciences, Inc., is a clinical-stage biopharmaceutical company developing drugs to treat RNA viruses, which are responsible for 80% of viral diseases worldwide

College Park, United StatesFounded 2020Health

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Altesa BioSciences

Altesa BioSciences, Inc. is a clinical stage biopharmaceutical company focused on developing drugs to treat RNA viruses, which are responsible for 80% of viral diseases globally. The company targets a range of respiratory viruses including Rhinovirus, Influenza, Respiratory Syncytial Virus (RSV), as well as other significant viral threats like Dengue, Yellow Fever, Ebola, and SARS-CoV-2 (COVID-19). Altesa BioSciences operates in the biopharmaceutical market, serving healthcare providers, patients, and research institutions. The company's business model revolves around the research and development (R&D) of antiviral drugs, leveraging a Sponsored Research Agreement with Emory DRIVE to access a robust R&D pipeline and industry-trained scientists. Revenue is generated through the development and eventual commercialization of these antiviral treatments. The leadership team includes experts with extensive experience in virology, biotechnology, and pharmaceutical development, such as Brett P. Giroir, MD, and George R. Painter, PhD. The company aims to make a significant impact on global health by providing safe and effective treatments for a variety of pathogenic viruses.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: College Park, United States
Employees: 20
Open positions: None listed
Dealroom signal: 81.8/100
Industry: Health
Sector: Health, Hard Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Feb 2026	$75M	$300M	Pitango Venture Capital · Sanofi · Medicxi · Forbion Capital Partners	↗
SERIES AOther financing	Jul 2023	$35M	$140M	Undisclosed	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Altesa BioSciences website traffic

Latest recorded traffic for Altesa BioSciences is 3.7K monthly website visits, up 27.6% over the last three months. Altesa BioSciences's team grew 300% over the past year.

Latest monthly visits3.7K 3-month web change+27.6% 1-year team growth+300%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
WAWatcherrAn AI health business solution for senior homes, residences and others	Aalst, Belgium	Operational	9	$4.8M	$8.8M
UTUp Devices and TechnologiesA patient-centric new technology and medical device development company	Madrid, Spain	Closed
PPPoint PressureDevice that offers auto-treatment for the patients and a new tool for therapists and doctors to improve the life of people with spasticity	Sant Cugat del Vallès, Spain	Operational
JHJSF HealthcareCommunication and workflow solution for healthcare professionals	Birmingham, United Kingdom	Operational
ITInicare Health TechnologyExplores the frontiers of medical science with wearable technology, artificial intelligence and cloud solutions to develop remote monitoring applications for use in the clinic and at home	Eindhoven, Netherlands	Operational
ISIndicate SolutionsDeveloping a cheap, reliable, rapid, and easy-to-use device to detect DNA mutations in the blood of cancer patients at POC, allowing patients tailored treatment decisions immediately	San Sebastián, Spain	Operational
MOMobiledoctorAims to create a healthy world by providing healthcare services that touch hearts	Seoul, South Korea	Operational
BRBrainGuardPredicts migraines by unobtrusive monitoring of hemodynamic signals helping migraineurs to improve their quality of life	Pozuelo de Alarcón, Spain	Operational